Exchange: NASDAQ·Updated 04:41 PM EST

DFTX Earnings

Latest Earnings Results: Q3 '26

Reported: Nov 09

Estimated EPS

-$0.56

Reported EPS

-$0.37

Surprise

+34.27%

Estimated Rev

$0M

Reported Rev

---

Surprise

---

Definium Therapeutics reported Q3 2026 research and development expenses of $46.1M and general and administrative expenses of $26.1M; net loss was $51M, or $0.37 basic per share.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.50
--
--
N/A
Q3 '26
-$0.56
-$0.37
34.27%
BEAT
Q2 '26
-$0.54
-$1.44
-166.19%
MISSED
Q1 '26
-$0.49
-$0.71
-44.27%
MISSED
Q4 '25
-$0.48
-$0.51
-5.44%
MISSED

Advertisement|Remove ads.